NIKKEI 225
39,346.92 +559.54 (+1.44%) HANG SENG
19,641.10 +87.49 (+0.45%) CRUDE OIL
80.02 -0.04 (-0.05%) GOLD FUTURES
2,439.90 +22.50 (+0.93%) DOW
40,003.59 +134.19 (+0.34%) Bitcoin GBP
52,478.68 -392.17 (-0.74%)
AMGN Jun 2025 200.000 put
| Previous close | 4.0000 |
| Open | 4.0000 |
| Bid | 1.5200 |
| Ask | 4.0500 |
| Strike | 200.00 |
| Expiry date | 2025-06-20 |
| Day's range | 4.0000 - 4.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 238 |
PR NewswireNEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared
ZacksAmgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
